A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AG-181 in Healthy Participants
Latest Information Update: 26 Dec 2025
At a glance
- Drugs AG 181 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Agios Pharmaceuticals
Most Recent Events
- 23 Dec 2025 Status changed from recruiting to completed.
- 12 Nov 2025 Planned End Date changed from 1 Oct 2025 to 1 Mar 2026.
- 12 Nov 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Mar 2026.